Alkermes (ALKS) revenue

Revenue · fiscal 2025
$1.48B

Alkermes (ALKS) reported revenue of $1.48B in fiscal 2025 (the year ended December 31, 2025). That is 5.2% lower than the $1.56B of fiscal 2024. Figures as of 18 Nov 2026, 09:09 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Revenue, fiscal 2025
$1.48B
Change on fiscal 2024
−5.2%
Growth, 5 years
+7.3% a year
Growth, 10 years
+8.9% a year
Highest on record
$1.66Bfiscal 2023
Lowest on record
$178.28Mfiscal 2010
Fiscal years on record
172010–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Alkermes revenue, in more detail

Over the five fiscal years to 2025 revenue grew at a compound 7.3% a year; over ten years the rate was 8.9% a year. Across the 17 fiscal years on record (2010–2025), the highest was $1.66B in fiscal 2023 and the lowest $178.28M in fiscal 2010.

History · 17 fiscal years

Revenue by fiscal year

Alkermes revenue, year by year

Alkermes (ALKS) revenue by fiscal year
Fiscal yearRevenueChangeYear ended
2025$1.48B 5.2% down
2024$1.56B 6.4% down
2023$1.66B 49.6% up
2022$1.11B 5.3% down
2021$1.17B 13.0% up
2020$1.04B 11.3% down
2019$1.17B 7.0% up
2018$1.09B 21.1% up
2017$903.37M 21.1% up
2016$745.69M 18.7% up
2015$628.34M 1.5% up
2014$618.79M 3.8% up
2013$596.33M—
2013$575.55M 47.6% up
2012$389.98M 108.9% up
2011$186.64M 4.7% up
2010$178.28M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.

How to read it

Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.

Revenue at health care companies of similar size

Revenue of Alkermes and comparable companies
CompanyRevenueFiscal year
Alkermes ALKS$1.48B2025
PACS Group PACS$5.29B2025
Kiniksa Pharmaceuticals International KNSA$677.56M2025
ImmunityBio IBRX$113.29M2025
Cytokinetics CYTK$88.04M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ALKS

Alkermes, figure by figure

Alkermes (ALKS) overview: price, valuation and scorecardAll health care companies by market value

Alkermes revenue: questions and answers

What is Alkermes's revenue?

Alkermes (ALKS) reported revenue of $1.48B in fiscal 2025 (the year ended December 31, 2025). That is 5.2% lower than the $1.56B of fiscal 2024.

What is the growth rate of Alkermes's revenue?

Over the five fiscal years to 2025 revenue grew at a compound 7.3% a year; over ten years the rate was 8.9% a year.

What are the highest and lowest revenue figures on record for Alkermes?

Across the 17 fiscal years on record (2010–2025), the highest was $1.66B in fiscal 2023 and the lowest $178.28M in fiscal 2010.

How is Alkermes's revenue calculated?

Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Alkermes it is on record here for 17 fiscal years, 2010 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Alkermes (ALKS) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/ALKS/revenue

Underlying data: the company's filings with the SEC and Yahoo Finance.